CMF
NVCR icon

Counterpoint Mutual Funds’s NovoCure NVCR Stock Holding History

Counterpoint Mutual Funds’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
66,849
+17,467
+35% +$264K 0.1% 78
2026
Q1 		$538K Buy
49,382
+10,777
+28% +$135K 0.08% 174
2025
Q4 		$499K Buy
38,605
+7,244
+23% +$93K 0.04% 182
2025
Q3 		$405K Buy
+31,361
New +$419K 0.03% 214
2025
Q1 		– Sell
-24,892
Closed -$742K – 373
2024
Q4 		$742K Sell
24,892
-4,354
-15% -$92.1K 0.09% 75
2024
Q3 		$457K Buy
29,246
+17,605
+151% +$319K 0.09% 106
2024
Q2 		$199K Sell
11,641
-36,005
-76% -$633K 0.05% 208
2024
Q1 		$745K Buy
47,646
+19,489
+69% +$287K 0.18% 8
2023
Q4 		$420K Buy
28,157
+20,686
+277% +$277K 0.16% 9
2023
Q3 		$121K Buy
+7,471
New +$215K 0.1% 169

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Counterpoint Mutual Funds's NVCR Position: Q2 2026 in Review

Counterpoint Mutual Funds increased its NovoCure (NVCR) stake by 35% in Q2 2026, buying an estimated $264K and bringing the position to 66,849 shares worth $1.01M. The position accounts for 0.1% of the portfolio, ranked #78.

Counterpoint Mutual Funds first reported a position in NVCR in Q3 2023 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Counterpoint Mutual Funds held 66,849 shares of NovoCure worth $1.01M as of Q2 2026.
  • Counterpoint Mutual Funds bought 17,467 NovoCure shares in Q2 2026, an estimated $264K.
  • NovoCure made up 0.1% of Counterpoint Mutual Funds's portfolio in Q2 2026, its #78 holding.
  • Counterpoint Mutual Funds first reported a position in NovoCure in Q3 2023 and has held it in 10 quarters since.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q2 2026, filed 20 Jul 2026.